Questions for 5 April Investor Call, page-22

Can the Board please provide a more detailed explanation of the significance of the clinical study results reported to the ASX on 9 March 2018, and in particular: (1) What is the short-term and long-term commercial significance of these results for the Company; (2) Have the results of the study been presented to any pharmaceutical companies and, if so, how have these results been received by those companies?; (3) Does the Board anticipate further clinical trials being conducted by such companies pursuant to a formal agreement with OBJ? (4) What revenues, both short-term and long-term, does the Board foresee being derived from this application of the Company's magnetophoresis technology?